Medpace beats Q3 estimates but guides below on revenue
Medpace Holdings (MEDP) reported Q3 adjusted earnings of $4.84 per share, beating estimates by $0.40, with revenue of $716.0 million, up 8.5% YoY. Full-year 2026 revenue guidance of $2.835B-$2.855B fell below analyst consensus, causing shares to drop 1.9% in after-hours trading. The company also announced a new $1.0B stock repurchase program.
How this was made
The 30-second read
Why it matters
Traders should focus on the guidance gap versus consensus (revenue midpoint below expectations) and whether the stronger EPS outlook and backlog growth can stabilize the stock after the initial after-hours selloff.
Market read
This is a classic beat-and-miss setup: earnings beat supports the story, but the revenue guidance midpoint below consensus is the immediate driver of negative sentiment.
What to watch
Net new business awards ($873.4M) and backlog ($3.167B) increased, suggesting revenue visibility may improve later in the year even if the current full-year midpoint is slightly conservative.
Background
Medpace is a clinical contract research organization, and the article reports its Q3 results plus full-year 2026 guidance and a new $1.0B buyback authorization.
Ticker impact
Medpace (MEDP) beat Q3 EPS and revenue estimates but guided full-year revenue to a midpoint below consensus, driving after-hours weakness.
Likely downside pressure as investors reprice full-year revenue growth expectations around the below-consensus midpoint.
The article cites a Q3 beat plus a full-year revenue midpoint of $2.845B versus $2.852B consensus, and notes shares slipped 1.9% after hours.
Market effects
CRO peers may see read-across on demand durability and pricing power if investors treat the revenue guide as a signal for industry growth.
Limited direct regional spillover; impact is primarily single-name within US healthcare services/CROs.
Modest, as CRO guidance affects global clinical outsourcing sentiment but the article provides no cross-border policy or macro catalyst.
Counterpoint
The company still raised/maintained profitability metrics (EBITDA margin up, EPS midpoint above consensus) and reported strong net new awards and backlog growth, which could offset the revenue guide disappointment.
Key entities
- companyMedpace Holdings Inc
Reported Q3 adjusted EPS and revenue above estimates, but guided full-year revenue below consensus midpoint.
- governanceBoard of Directors
Approved a new $1.0B stock repurchase authorization effective October 20, 2026 through December 31, 2028.
